83 documents

Read All
23:40 , Dec 14, 2018 |  BioCentury  |  Emerging Company Profile

ExCellThera’s safer allogeneic transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have...
Read More
22:56 , Dec 5, 2018 |  BC Extra  |  Tools & Techniques

Proteogenomic screen identifies non-mutated tumor-specific antigens

A University of Montreal team has developed a proteogenomic screen that identifies mutated and non-mutated tumor-specific TCR antigens, including those arising from normally non-coding nucleotide sequences. The technique could help develop T cell immunotherapies targeting...
Read More
18:48 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
Read More
01:04 , Dec 8, 2017 |  BC Innovations  |  Translation in Brief

ADAM and Ephrin

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by...
Read More
13:53 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; melanoma Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment,...
Read More
19:02 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Mouse studies suggest inhibiting ADAM10 could help treat idiopathic pulmonary fibrosis (IPF). In a mouse model of IPF, an ADAM10 inhibitor tool compound decreased fibrosis in the lung and increased survival compared...
Read More
19:01 , May 8, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts SMARCD2 -knockout mouse and zebrafish models could be used to screen therapies for neutrophil-specific granule deficiency, a congenital immunodeficiency. Whole-exome sequencing in four patients identified splice site and frameshift mutations in...
Read More
20:05 , Jan 12, 2017 |  BC Innovations  |  Emerging Company Profile

Looking beyond VEGF

SemaThera Inc. launched this week to develop a recombinant SEMA3A trap to treat vascular pathologies in the large fraction of diabetic macular edema (DME) patients who don’t respond to marketed anti- VEGF therapies. Semaphorins are...
Read More
07:00 , Sep 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Stearoyl-CoA desaturase-1 (SCD1)

Neurology INDICATION: Alzheimer's disease (AD) Mouse and human sample studies suggest inhibiting SCD1 could help treat AD. Numbers of triglyceride-containing lipid droplets were higher in the forebrain subventricular zones of AD patients than in healthy...
Read More
07:00 , Sep 3, 2015 |  BC Innovations  |  Targets & Mechanisms

Low-fat brain

While most of the focus in Alzheimer's disease is on slowing or stopping the degeneration of neurons, a team at the University of Montreal has found that one cause of the disease could lie in...
Read More